These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 25963410)
1. Multiple oncogenic mutations related to targeted therapy in nasopharyngeal carcinoma. Zhang JW; Qin T; Hong SD; Zhang J; Fang WF; Zhao YY; Yang YP; Xue C; Huang Y; Zhao HY; Ma YX; Hu ZH; Huang PY; Zhang L Chin J Cancer; 2015 Apr; 34(4):177-83. PubMed ID: 25963410 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium. Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224 [TBL] [Abstract][Full Text] [Related]
3. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231 [TBL] [Abstract][Full Text] [Related]
4. Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay. Su J; Zhang XC; An SJ; Zhong WZ; Huang Y; Chen SL; Yan HH; Chen ZH; Guo WB; Huang XS; Wu YL Chin J Cancer; 2014 Jul; 33(7):346-50. PubMed ID: 24823994 [TBL] [Abstract][Full Text] [Related]
5. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Gasch C; Bauernhofer T; Pichler M; Langer-Freitag S; Reeh M; Seifert AM; Mauermann O; Izbicki JR; Pantel K; Riethdorf S Clin Chem; 2013 Jan; 59(1):252-60. PubMed ID: 23136247 [TBL] [Abstract][Full Text] [Related]
6. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target-directed therapy. Kim HK; Lee HY; Choi YL; Choi SJ; Choi H; Lee J; Han J; Ahn MJ; Lee KS; Kim J Anticancer Res; 2014 Feb; 34(2):707-14. PubMed ID: 24511003 [TBL] [Abstract][Full Text] [Related]
7. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512 [TBL] [Abstract][Full Text] [Related]
8. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer. Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442 [TBL] [Abstract][Full Text] [Related]
9. Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma. Wen YS; Cai L; Zhang XW; Zhu JF; Zhang ZC; Shao JY; Zhang LJ Medicine (Baltimore); 2014 Dec; 93(29):e296. PubMed ID: 25546673 [TBL] [Abstract][Full Text] [Related]
10. Oncogenic mutations and microsatellite instability phenotype predict specific anatomical subsite in colorectal cancer patients. Corso G; Pascale V; Flauti G; Ferrara F; Marrelli D; Roviello F Eur J Hum Genet; 2013 Dec; 21(12):1383-8. PubMed ID: 23572025 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752 [TBL] [Abstract][Full Text] [Related]
12. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718 [TBL] [Abstract][Full Text] [Related]
13. Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. Jiang N; Liu N; Yang F; Zhou Q; Cui R; Jiang W; He Q; Li W; Guo Y; Zeng J; Yun J; Chen X; Zhou B; Sun Y; Wang H; Chen ZG; Ma J Oncol Rep; 2014 Oct; 32(4):1661-9. PubMed ID: 25109408 [TBL] [Abstract][Full Text] [Related]
14. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Schönleben F; Allendorf JD; Qiu W; Li X; Ho DJ; Ciau NT; Fine RL; Chabot JA; Remotti HE; Su GH Pancreas; 2008 Mar; 36(2):168-72. PubMed ID: 18376308 [TBL] [Abstract][Full Text] [Related]
15. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847 [TBL] [Abstract][Full Text] [Related]
16. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378 [TBL] [Abstract][Full Text] [Related]
17. Oncogene alterations in endometrial carcinosarcomas. Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. Ali SM; Yao M; Yao J; Wang J; Cheng Y; Schrock AB; Chirn GW; Chen H; Mu S; Gay L; Elvin JA; Suh J; Miller VA; Stephens PJ; Ross JS; Wang K Cancer; 2017 Sep; 123(18):3628-3637. PubMed ID: 28581676 [TBL] [Abstract][Full Text] [Related]
19. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136 [TBL] [Abstract][Full Text] [Related]
20. Construction of a reference material panel for detecting Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]